Tres Cantos Open Lab: celebrating a decade of innovation in collaboration to combat endemic infectious diseases

Calderón, Félix; Ballell, Lluís; Barrós, David Miranda; Bilbe, Graeme; Cammack, N.; Gabarro, R.; Halsey, Audra; Heaton, Penny M.; Kang, Gagandeep; Mizrahi, Valerie; Nathan, Carl; Strange, Mike; Williams, Pauline; Winzeler, Elizabeth A.; Fairlamb, Alan H.

doi:10.1038/d41573-021-00143-2

Cited by 2 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For this reason, a key point of this whole text is a plea to include in these consortium academic chemists who can also be important sources of intellectual property. The European Lead Factory facilities [99,187-189], the infection innovation consortium (IICON) [190] or the now decade-old GSK initiative at the Tres Cantos open lab [191], as well as many NIH initiatives such as the Antiviral Drug Discovery Centers [192] are also available for such projects. The well-illustrated perspectives on the organization of such public private partnerships, often focusing on neglected diseases, are worth consulting [193][194][195][196][197] as well as a recent survey on the contributions of private and public sector to biopharmaceutical research [198].…”

Section: Suggestions To Improve the Output Of Academic Drug Discovery...mentioning

confidence: 99%

On drug discovery against infectious diseases and academic medicinal chemistry contributions

Janin¹

2022

Beilstein J. Org. Chem.

View full text Add to dashboard Cite

This perspective is an attempt to document the problems that medicinal chemists are facing in drug discovery. It is also trying to identify relevant/possible, research areas in which academics can have an impact and should thus be the subject of grant calls. Accordingly, it describes how hit discovery happens, how compounds to be screened are selected from available chemicals and the possible reasons for the recurrent paucity of useful/exploitable results reported. This is followed by the successful hit to lead stories leading to recent and original antibacterials which are, or about to be, used in human medicine. Then, illustrated considerations and suggestions are made on the possible inputs of academic medicinal chemists. This starts with the observation that discovering a “good” hit in the course of a screening campaign still rely on a lot of luck – which is within the reach of academics –, that the hit to lead process requires a lot of chemistry and that if public–private partnerships can be important throughout these stages, they are absolute requirements for clinical trials. Concerning suggestions to improve the current hit success rate, one academic input in organic chemistry would be to identify new and pertinent chemical space, design synthetic accesses to reach these and prepare the corresponding chemical libraries. Concerning hit to lead programs on a given target, if no new hits are available, previously reported leads along with new structural data can be pertinent starting points to design, prepare and assay original analogues. In conclusion, this text is an actual plea illustrating that, in many countries, academic research in medicinal chemistry should be more funded, especially in the therapeutic area neglected by the industry. At the least, such funds would provide the intensive to secure series of hopefully relevant chemical entities which appears to often lack when considering the results of academic as well as industrial screening campaigns.

show abstract

Section: Suggestions To Improve the Output Of Academic Drug Discovery...mentioning

confidence: 99%

On drug discovery against infectious diseases and academic medicinal chemistry contributions

Janin¹

2022

Beilstein J. Org. Chem.

View full text Add to dashboard Cite

show abstract

“…Established in 2010 by GlaxoSmithKline (GSK), the Open Lab model has proven its utility and durability over the last decade ( GlaxoSmithKline, 2010 ). A companion article in Nature Reviews Drug Discovery describes the Open Lab’s scientific accomplishments ( Calderón et al, 2021 ). Here we describe the Open Lab’s approach and the organizational structure that sustains it.…”

mentioning

confidence: 99%

Surmounting structural barriers to tackle endemic infectious diseases

Calderón

Fairlamb

Strange

et al. 2021

Journal of Experimental Medicine

Self Cite

View full text Add to dashboard Cite

A unique experiment in bringing academic and industrial scientists together to tackle endemic infectious diseases has proved a success. The Tres Cantos Open Lab Foundation, guided and advised by independent experts, funds extended stays of academics at the campus of a pharmaceutical company, where they access the firm’s resources in partnership with company scientists. Progress in tackling tuberculosis, protozoal infections, and enteric bacterial diseases has sustained the decade-long evolution of the model, whose distinctive features complement other public–private partnerships with similar goals.

show abstract

Tres Cantos Open Lab: celebrating a decade of innovation in collaboration to combat endemic infectious diseases

Cited by 2 publications

References 4 publications

On drug discovery against infectious diseases and academic medicinal chemistry contributions

On drug discovery against infectious diseases and academic medicinal chemistry contributions

Surmounting structural barriers to tackle endemic infectious diseases

Contact Info

Product

Resources

About